Join

Compare · BDX vs FEMY

BDX vs FEMY

Side-by-side comparison of Becton Dickinson and Company (BDX) and Femasys Inc. (FEMY): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BDX and FEMY operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • BDX is the larger of the two at $41.33B, about 127.0x FEMY ($325.5M).
  • Over the past year, BDX is down 13.0% and FEMY is down 66.3% - BDX leads by 53.4 points.
  • BDX has been more active in the news (10 items in the past 4 weeks vs 2 for FEMY).
  • BDX has more recent analyst coverage (25 ratings vs 3 for FEMY).
PerformanceBDX-12.95%FEMY-66.33%
2025-06-09+0.00%2026-06-08
MetricBDXFEMY
Company
Becton Dickinson and Company
Femasys Inc.
Price
$150.14-0.71%
$5.37+1661.23%
Market cap
$41.33B
$325.5M
1M return
-2.01%
-40.01%
1Y return
-12.95%
-66.33%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NYSE
NASDAQ
IPO
2021
News (4w)
10
2
Recent ratings
25
3
BDX

Becton Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

FEMY

Femasys Inc.

Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Latest BDX

Latest FEMY